Edge Advisors’s Idexx Laboratories IDXX Stock Holding History

Edge Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$146K	Hold	670	–	–	0.01%	354
2018 Q1	$128K	Hold	670	–	–	0.01%	376
2017 Q4	$104K	Sell	670 -28	-4%	-$4.41K	0.01%	390
2017 Q3	$108K	Buy	698 +28	+4%	+$4.43K	0.01%	372
2017 Q2	$108K	Hold	670	–	–	0.01%	385
2017 Q1	$103K	Sell	670 -265	-28%	-$36.5K	0.01%	401
2016 Q4	$109K	Buy	+935	New	+$107K	0.01%	367

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FEF

Fundsmith Equity Fund Stamford, Connecticut $13.4B AUM

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Edge Advisors's IDXX Position: Q2 2018 in Review

Edge Advisors held its Idexx Laboratories (IDXX) position steady in Q2 2018 at 670 shares worth $146K. The position accounts for 0.01% of the portfolio, ranked #354.

Edge Advisors first reported a position in IDXX in Q4 2016 and has held it in 7 quarters since. 664 funds tracked by Wall St. Rank hold IDXX as of Q2 2018.

Edge Advisors held 670 shares of Idexx Laboratories worth $146K as of Q2 2018.
Edge Advisors left its Idexx Laboratories share count unchanged in Q2 2018.
Idexx Laboratories made up 0.01% of Edge Advisors's portfolio in Q2 2018, its #354 holding.
Edge Advisors first reported a position in Idexx Laboratories in Q4 2016 and has held it in 7 quarters since.
664 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.